# InFlectis BioScience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inflectis-bioscience

- Industry: Pharmaceuticals
- Headquarters: Nantes, France
- Website: www.inflectisbioscience.com
- Total disclosed funding: $6.2M
- Latest round: Series A (Jan 5, 2017)
- Investors on record: 5

## About

InFlectis BioScience is a biotechnology company focused on developing therapeutics to treat protein misfolding diseases, particularly within neurological disorders, through innovative small molecules.Founded in 2013 and headquartered in Nantes, France, InFlectis BioScience specializes in the development of therapies for neurological conditions. The company was co-founded by Philippe Guédat, who has a history of entrepreneurship in the biotech sector. In January 2017, the firm secured EUR 4.50 mn in a Series A funding round led by CM-CIC Capital Finance and Remiges Ventures, among other investors. The total amount raised to date stands at EUR 4.50 mn, with a current company valuation of EUR 20.86 mn.InFlectis BioScience develops therapeutics aimed at addressing protein misfolding diseases, especially neurological disorders such as Amyotrophic Lateral Sclerosis (ALS), Charcot-Marie-Tooth disease (CMT), and Multiple Sclerosis (MS). The company focuses on multifunctional, brain-penetrant small molecules that target various mechanisms involved in these conditions to mitigate disease progression and enhance patient outcomes. The therapeutic offerings are directed towards individuals battling these diseases and healthcare professionals administering the treatments, targeting markets in Europe, North America, and Asia.InFlectis BioScience reported a revenue of EUR 5,534.60 mn for the year 2022, with an EBITDA of EUR -2,796,239.60 for the same year. Its revenue model is structured around partnerships and collaborations with healthcare providers and research institutions, focusing on the commercialization of its therapeutic candidates.InFlectis BioScience plans to leverage its recent funding to further develop its pipeline of products aimed at innovative treatments for neurological disorders. The company is looking to expand into additional geographic markets, specifically targeting regions in Europe and North America by 2025. Funding from the EUR 4.50 mn Series A round will support these initiatives, strengthening partnerships and facilitating the development of new therapeutic options.

## Funding rounds

- Series A, Jan 5, 2017, $4.7M — Credit Mutuel Equity, Go Capital, Remiges Ventures, Participations Besançon
- Seed, Feb 5, 2015, $1.4M — Go Capital, Bpifrance Investissement, Participations Besançon

## Investors

- Go Capital — Seed, Series A
- Bpifrance Investissement (https://capitalatlas.ai/funds/bpifrance-investissement) — Seed
- Participations Besançon — Seed, Series A
- Credit Mutuel Equity (https://capitalatlas.ai/funds/credit-mutuel-equity) — Series A
- Remiges Ventures (https://capitalatlas.ai/funds/remiges-ventures) — Series A